ProCE Banner Activity

SPOTLIGHT: Phase III Study of First-line Zolbetuximab + mFOLFOX6 for Advanced CLDN18.2+/HER2- Gastric/Gastroesophageal Junction Adenocarcinoma

Conference Coverage

Addition of zolbetuximab to mFOLFOX6 improved PFS and OS compared with mFOLFOX alone for previously untreated patients with advanced CLDN18.2+/HER2- gastric/gastroesophageal junction adenocarcinoma.

Released: January 25, 2023

Expiration: January 24, 2024

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp.

Seagen Inc.